Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
A molecule that is no longer BPC-157
1c or the monothiol mechanism (i) from Fig
doi: 10.1159/000485089 187 McNeilEMAstellKRRitchieA-MShaveSHoustonDRBakraniaPet al
Important Safety Information Do not use AOD-9604 if you: Have a known hypersensitivity to growth hormone fragments or any component of the formulation Have active malignancy (cancer that is currently being treated or monitored) Are pregnant or breastfeeding (insufficient safety data) Have a history of severe allergic reactions to peptide therapies Common side effects (typically mild and transient): Headache, mild gastrointestinal disturbances (flatulence, mild diarrhea at higher doses), upper respiratory tract symptoms, injection site reactions (redness, mild discomfort) Seek medical attention if you experience: Signs of allergic reaction (hives, difficulty breathing, swelling of face or throat), persistent gastrointestinal symptoms, unexplained significant changes in energy, mood, or physical symptoms Clinical Safety Data Safety studies involving approximately 900 participants across six randomized controlled trials documented that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo across most parameters
Building on these motivations, the "Empowering Women Through Cooperatives Project" (2021-2024), led by Trkiye's Ministry of Agriculture and Forestry with EU co-financing, established the "Womens Cooperative Network." This project marks a significant milestone for womens cooperatives in Trkiye
